



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C12N 15/63 (2006.01) A61P 35/00 (2006.01)
C12N 15/13 (2006.01)

(21) International Application Number:

PCT/CN2017/112832

(22) International Filing Date:

24 November 2017 (24.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicants: EUCURE (BEIJING) BIOPHARMA CO., LTD [CN/CN]; Room 306, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). BEIJING BIOCYTOGEN CO., LTD [CN/CN]; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).

(72) Inventors: YANG, Yi; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). GUO, Yanan; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). CHEN, Yunyun; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). XIE, Jingshu; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).

DONG, Chunyan; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). YANG, Fang; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). LU, Chengyuan; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). CHENG, Xiaodong; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). SHEN, Yuele; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). NI, Jian; Room 1201-1210, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).

(74) Agent: BEIJING LINKTEC IP LAW AGENT (SPECIAL GENERAL PARTNER); Room 1705, Baoyuan Buiding, (Zhongguancun Energy and Safety Science Park), No. 16 Qinghua East Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ANTI-OX40 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: This disclosure provides anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))